Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Ovarian Neoplasms 3Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Advanced Malignant Solid Neoplasm 1

Interventions

Cyclophosphamide 24fludarabine phosphate 22Filgrastim 15Gemcitabine 14fludarabine 13Rituximab 13Brentuximab Vedotin 13Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Bortezomib 10Mycophenolic Acid 9Melphalan 9Etoposide 9Busulfan 9Sirolimus 8Lenalidomide 8Azacitidine 8Nivolumab 7Dexamethasone 7pembrolizumab 6Radiotherapy 6Cytarabine 6Antilymphocyte Serum 6romidepsin 5aldesleukin 5Panobinostat 5Leucovorin 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Hodgkin Disease × Pharmacogenomic Variants × Clear all
NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1 Completed
50 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03013933 2024-02-22

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

City of Hope Medical Center

Phase 1 Completed
29 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡